US FDA Generic Drug Applications Will Cost Less In FY 2020
Executive Summary
Increases in the number of expected ANDA submissions, facilities and entities holding approved applications means lower user fees in most GDUFA II categories starting 1 October; program fee will see the largest percentage drop, amounting to savings of $200,000 for large companies.
You may also be interested in...
GDUFA Sees First-Ever Fee Spending Decrease
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.
Generic Drug User Fee Program Sees First-Ever Fee Spending Decrease, FTE Decline
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.
US FDA Generic Approvals Break 900 Barrier In FY 2019
The record number of full ANDA approvals also exceeded submissions for the first time since GDUFA was enacted.